
View Now | CP-RND: An Introduction to the Patient Community

Hosted by the C-Path team, you can [view this recorded webinar](#) to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.

This webinar and patient-focused roundtable will deliver an enhanced understanding of:

- The CP-RND strategic plan, its stakeholder groups and program deliverables
- The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
- Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community

Speakers and panelists included:



Ronald J. Bartek
Co-founder/President,
Friedreich's Ataxia Research
Alliance



Lauren Boak, PhD
Lifecycle Leader, GPS NSRD,
Roche



Michelle Campbell, PhD
Associate Director, Stakeholder
Engagement and Clinical
Outcomes, U.S. Food and Drug
Administration



**Jacqueline Corrigan-Curay, JD,
MD**
Principal Deputy Center Director,
Center for Drug Evaluation and
Research, U.S. Food and Drug
Administration



Philip Green
ALS Patient Advocate



**Collin Hovinga, PharmD, MS,
FCCP**
Vice President of the Rare and
Orphan Disease Programs,
Critical Path Institute



Walter Koroshetz, MD
Director, National Institute of
Neurological Disorders and
Stroke



Terina N. Martinez, PhD
Executive Director, Critical Path
for Rare Neurodegenerative
Diseases, Critical Path Institute



**Klaus Romero, MD, MS,
FCCP**
Chief Science Officer;
Executive Director of Clinical
Pharmacology, Critical Path
Institute



Celia Witten, MD, PhD
Deputy Director, Center for
Biologics Evaluation and
Research, U.S. Food and Drug
Administration